Selected current grants:
1. March 1, 2026 - 2031: NPI Keith Fowke, PIs Julie Lajoie and Joshua Kimani, co-I’s Lyle McKinnon, Aida Sivro and co-I PDFs Titus Olukitibi and Kenneth Omollo., Other UM members includes cancer experts, Mark Nachtigal from Biochemistry and Human Genetics and Alon Altman from Obs and Gyne as well as international colleagues Marianne Mureithi from U of Nairobi, and community member Joyce Adhiambo from SWOP. ($2, 000, 000).
Inflammation, Sex Hormones, and Human Papillomavirus (HPV) Expression: Assessing their Relationship in Menopausal Women and Evaluating Interventions to Prevent Cervical Cancer in Older Women
2. April 1, 2025 - March 31st, 2026: Keith Fowke and Titus Olukitibi: Training grant from CIHR for their project “Increasing Capacity for Maternal and Pediatric Clinical Trials (IMPACT) in Canada.
3. June 1 2024 – March 31, 2029. Nominated Principal Applicant Julie Lajoie, Principal Applicant Alicia Berard, Co-Applicants Keith Fowke, Emmanuel Ho, Joshua Kimani, Monika Kowatsch, Leigh McClarty. The impact of Depot Medroxyacetate (DMPA) on inflammation in female sex workers: implications for HIV susceptibility. Canadian Institutes for Health Research. Project Grant. $1,225,000.
4. April 1, 2024- March 31, 2029. Nominated Principal Investigator – Keith Fowke. Co-applicants – Joshua Kimani, Julie Lajoie, Identifying immune markers of HPV viral clearance. Canadian Institutes for Health Research. Project Grant. $956,250.
5. March 1, 2024- March 31, 2028. Director Peter Pelka, Co-Director Maya Shmulevitz. Scientific Team members: Keith R. Fowke, Elham Salimi, Sue Tsai, Lorne D. Tyrrell, Ryan Noyce, Kenneth (Jason) Kindrachuk, Hector De la Hoz Siegler, Troy Baldwin, Suresh Tikoo, Brian Mark, Jorg Stetefeld, Craig Jenne, Xiao-Jian Yao, Vanessa Meier-Stephenson, Barbara Porto. Viral vector vaccine platforms for rapid response to future pandemics. Canadian Biomedical Research Fund Total Funds for research operations $18,937,327 ($565,286.75 of which is for research operating funds to the Fowke lab over 5 years). Biomedical Research Innovation Fund (BRIF), for PRAIRIE One Health Emerging Respiratory Disease Centre (POHERD) and Containment Level 3 (Agriculture) containment facility, $16,050,785. PRAIRIE Biologics Accelerator for vaccine production $22,011,888.
6. Jan 1, 2024- Dec 31, 2028. Principal Applicant – Keith Fowke. Co-applicants - Denice Bay, Marianne Mureithi. University of Nairobi/University of Manitoba Graduate Training Program in Medical Microbiology. Global Affairs Canada/Universities Canada, Canadian International Development Scholarships (BCDI 2030). $444,984.
7. Oct 1, 2023- Sept 30, 2026. Nominated Principal Investigator – Keith Fowke. Co-applicants – Joshua Kimani; co-investigators – Julie Lajoie, Alberto Severini, Aida Sivro. Inflammation and HPV persistence. Canadian Institutes for Health Research. STBBIs other than HIV and Hep C. $450,000.
8. Oct 1, 2023- Sept 30, 2026. Nominated Principal Investigator Xiao-Jian Yao. Co-applicants – Keith Fowke, Xi Yang, Alberto Severini. Development of a multivalent rVSV vaccine against different Chlamydia trachomatis urogenital infections. Canadian Institutes for Health Research. STBBIs other than HIV and Hep C. $450,000.
Inflammation, Sex Hormones, and Human Papillomavirus (HPV) Expression: Assessing their Relationship in Menopausal Women and Evaluating Interventions to Prevent Cervical Cancer in Older Women
2. April 1, 2025 - March 31st, 2026: Keith Fowke and Titus Olukitibi: Training grant from CIHR for their project “Increasing Capacity for Maternal and Pediatric Clinical Trials (IMPACT) in Canada.
3. June 1 2024 – March 31, 2029. Nominated Principal Applicant Julie Lajoie, Principal Applicant Alicia Berard, Co-Applicants Keith Fowke, Emmanuel Ho, Joshua Kimani, Monika Kowatsch, Leigh McClarty. The impact of Depot Medroxyacetate (DMPA) on inflammation in female sex workers: implications for HIV susceptibility. Canadian Institutes for Health Research. Project Grant. $1,225,000.
4. April 1, 2024- March 31, 2029. Nominated Principal Investigator – Keith Fowke. Co-applicants – Joshua Kimani, Julie Lajoie, Identifying immune markers of HPV viral clearance. Canadian Institutes for Health Research. Project Grant. $956,250.
5. March 1, 2024- March 31, 2028. Director Peter Pelka, Co-Director Maya Shmulevitz. Scientific Team members: Keith R. Fowke, Elham Salimi, Sue Tsai, Lorne D. Tyrrell, Ryan Noyce, Kenneth (Jason) Kindrachuk, Hector De la Hoz Siegler, Troy Baldwin, Suresh Tikoo, Brian Mark, Jorg Stetefeld, Craig Jenne, Xiao-Jian Yao, Vanessa Meier-Stephenson, Barbara Porto. Viral vector vaccine platforms for rapid response to future pandemics. Canadian Biomedical Research Fund Total Funds for research operations $18,937,327 ($565,286.75 of which is for research operating funds to the Fowke lab over 5 years). Biomedical Research Innovation Fund (BRIF), for PRAIRIE One Health Emerging Respiratory Disease Centre (POHERD) and Containment Level 3 (Agriculture) containment facility, $16,050,785. PRAIRIE Biologics Accelerator for vaccine production $22,011,888.
6. Jan 1, 2024- Dec 31, 2028. Principal Applicant – Keith Fowke. Co-applicants - Denice Bay, Marianne Mureithi. University of Nairobi/University of Manitoba Graduate Training Program in Medical Microbiology. Global Affairs Canada/Universities Canada, Canadian International Development Scholarships (BCDI 2030). $444,984.
7. Oct 1, 2023- Sept 30, 2026. Nominated Principal Investigator – Keith Fowke. Co-applicants – Joshua Kimani; co-investigators – Julie Lajoie, Alberto Severini, Aida Sivro. Inflammation and HPV persistence. Canadian Institutes for Health Research. STBBIs other than HIV and Hep C. $450,000.
8. Oct 1, 2023- Sept 30, 2026. Nominated Principal Investigator Xiao-Jian Yao. Co-applicants – Keith Fowke, Xi Yang, Alberto Severini. Development of a multivalent rVSV vaccine against different Chlamydia trachomatis urogenital infections. Canadian Institutes for Health Research. STBBIs other than HIV and Hep C. $450,000.
